MRK Dividends
Merck & Co., Inc. (MRK) pays $3.32 in dividends per share, with a current dividend yield of 2.80%. The company has dividend history for 15 consecutive years.
MRK Dividend Summary
2.80%
$3.32
45.48%
58.85%
Consecutive Years
15
Next Ex-Dividend Date
Jun 15, 2026
Next Payment Date
Jul 8, 2026
MRK Dividends per Share (Nominal History)
View full nominal table listThis step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.
MRK Dividends CAGR Chart
Merck & Co., Inc. (MRK)
Annual Dividend History
| Year | Dividend/Share | YoY Growth |
|---|---|---|
| 2026(YTD) | $1.70 | — |
| 2025 | $3.28 | +5.13% |
| 2024 | $3.12 | +5.41% |
| 2023 | $2.96 | +5.71% |
| 2022 | $2.80 | +7.27% |
| 2021 | $2.61 | +10.30% |
| 2020 | $2.37 | +9.73% |
| 2019 | $2.16 | +13.57% |
| 2018 | $1.90 | +5.29% |
| 2017 | $1.80 | +2.16% |
| 2016 | $1.77 | +2.21% |
| 2015 | $1.73 | +2.26% |
| 2014 | $1.69 | +2.31% |
| 2013 | $1.65 | +2.37% |
| 2012 | $1.61 | +8.33% |
| 2011 | $1.49 | +2.63% |
| 2010 | $1.45 | +0.00% |
| 2009 | $1.45 | +0.00% |
| 2008 | $1.45 | +0.00% |
| 2007 | $1.45 | +0.00% |
Quarterly Dividend History
| Quarter | Dividend/Share | YoY Growth |
|---|---|---|
| Q2 2026 | $0.85 | +4.94% |
| Q1 2026 | $0.85 | +4.94% |
| Q4 2025 | $0.85 | +4.94% |
| Q3 2025 | $0.81 | +5.19% |
| Q2 2025 | $0.81 | +5.19% |
| Q1 2025 | $0.81 | +5.19% |
| Q4 2024 | $0.81 | +5.19% |
| Q3 2024 | $0.77 | +5.48% |
| Q2 2024 | $0.77 | +5.48% |
| Q1 2024 | $0.77 | +5.48% |
| Q4 2023 | $0.77 | +5.48% |
| Q3 2023 | $0.73 | +5.80% |
| Q2 2023 | $0.73 | +5.80% |
| Q1 2023 | $0.73 | +5.80% |
| Q4 2022 | $0.73 | +5.80% |
| Q3 2022 | $0.69 | +6.15% |
| Q2 2022 | $0.69 | +6.15% |
| Q1 2022 | $0.69 | +11.25% |
| Q4 2021 | $0.69 | +11.25% |
| Q3 2021 | $0.65 | +11.67% |
| Q2 2021 | $0.65 | +11.67% |
| Q1 2021 | $0.62 | +6.56% |
| Q4 2020 | $0.62 | +6.56% |
| Q3 2020 | $0.58 | +10.91% |
Dividend Yield Metrics
- Current Yield
- 2.80%
- Average Yield (TTM)
- 2.80%
- Average Yield (3Y)
- 2.63%
- Forward Yield on Cost (3Y)
- 3.52%
- Forward Yield on Cost (5Y)
- 4.10%
- Forward Yield on Cost (10Y)
- 6.00%
Payout Ratio Analysis
- Payout Ratio (Current)
- 45.48%
- FCF Payout Ratio
- 58.85%
- Payout Ratio (3Y Avg)
- 735.12%
- Payout Ratio (5Y Avg)
- 460.96%
- FCF Payout (3Y Avg)
- 64.82%
- FCF Payout (5Y Avg)
- 62.20%
Dividend Coverage
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis